检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:张笑颜 薛璇玑 王兴斌 张富鑫 张新新[1] 郭增军[1] ZHANG Xiaoyan;XUE Xuanji;WANG Xingbin;ZHANG Fuxin;ZHANG Xinxin;GUO Zengjun(School of Pharmacy,Xi’an Jiaotong University,Shaanxi Key Laboratory of“Qiyao”Resources and Anti-tumor Activities,Xi’an 710061,China)
机构地区:[1]西安交通大学药学院,陕西省中医药管理局“七药”资源及抗肿瘤重点研究室,西安710061
出 处:《中国现代应用药学》2020年第10期1182-1186,共5页Chinese Journal of Modern Applied Pharmacy
基 金:中医药公共卫生服务补助专项“全国中药资源普查项目”(财社〔2017〕66号);中医药公共卫生服务补助资金第四次全国中药资源普查项目(财社〔2018〕43号)。
摘 要:目的考察大鼠灌胃九牛造提取物与鞣花酸单体后体内鞣花酸的药动学特征及差异。方法 SD大鼠分别灌胃九牛造提取物3 g·kg^-1与鞣花酸单体205.5 mg·kg^-1(含等量鞣花酸)后,在不同时间点采集血浆,通过HPLC测定鞣花酸的血药浓度,应用DAS2.0软件拟合大鼠体内鞣花酸的药动学模型,计算药动学参数。结果大鼠灌胃九牛造提取物后,拟合得到以下药动学参数:tmax=0.25h;Cmax=(1.32±0.30)mg·L^-1;AUC(0-t)=(2.55±0.54)mg·h·L^-1;AUC(0-∞)=(3.30±0.53)mg·h·L^-1;t1/2β=(69.32±2.37)h;大鼠灌胃给予鞣花酸单体后,tmax=0.50h;Cmax=(0.40±0.09)mg·L^-1;AUC(0-t)=(1.30±0.25)mg·h·L^-1;AUC(0-∞)=(1.81±0.23)mg·h·L^-1;t1/2β=(8.16±1.18)h。前者较后者达峰时间提前一半,达峰浓度和血药浓度-时间曲线下面积分别提高约3.30和1.46倍,末端消除半衰期延长约8.49倍。结论鞣花酸化合物在提取物和单体2种不同给药情况下,药动学行为存在明显差异。大鼠灌胃九牛造提取物后,与口服鞣花酸单体相比,鞣花酸化合物的生物利用度明显提高。OBJECTIVE To study the pharmacokinetic characteristics and differences of ellagic acid in rats after oral administration of Euphorbia hylonoma Hand-Mazz.extract and ellagic acid monomer.METHODS SD rats were intragastrically administered with 3 g·kg^-1 of Euphorbia hylonoma Hand-Mazz.extract and 205.5 mg·kg^-1 of ellagic acid monomer(containing an equal amount of ellagic acid).Plasma was collected at different time points and determined by HPLC.The pharmacokinetics of ellagic acid was applied to the blood concentration of ellagic acid by DAS 2.0 software.The pharmacokinetic parameters were calculated.RESULTS After the rats were given the Euphorbia hylonoma Hand-Mazz.extract,the following pharmacokinetic parameters were obtained:tmax=0.25 h;Cmax=(1.32±0.30)mg·L-1;AUC(0-t)=(2.55±0.54)mg·h·L^-1;AUC(0-∞)=(3.30±0.53)mg·h·L^-1;t1/2β=(69.32±2.37)h.However,the rats were given the ellagic acid monomer,the following pharmacokinetic parameters were obtained:tmax=0.50 h;Cmax=(0.40±0.09)mg·L^-1;AUC(0-t)=(1.30±0.25)mg·h·L^-1;AUC(0-∞)=(1.81±0.23)mg·h·L^-1;t1/2β=(8.16±1.18)h.The former was half the peak time of the latter,and the peak concentration and area under the curve is increased by about 3.30 and 1.46 times,respectively,and the half-life was extended by about 8.49 times.CONCLUSION There are significant differences in pharmacokinetic behavior between ellagic acid compounds in the two different administrations of extracts and monomers.After the rats were given the Euphorbia hylonoma Hand-Mazz.extract,compared with the oral ellagic acid monomer,the bioavailability of ellagic acid compounds is significantly improved.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.222